AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.100
+0.040 (1.94%)
At close: May 13, 2025, 4:00 PM
2.070
-0.030 (-1.43%)
Pre-market: May 14, 2025, 6:24 AM EDT

AbCellera Biologics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
May '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Market Capitalization
6268651,6572,8984,02710,832
Upgrade
Market Cap Growth
-49.90%-47.77%-42.83%-28.02%-62.83%-
Upgrade
Enterprise Value
842949522,1063,30510,829
Upgrade
Last Close Price
2.102.935.7110.1314.3040.24
Upgrade
PE Ratio
---18.2826.24127.29
Upgrade
Forward PE
----51.81-
Upgrade
PS Ratio
26.8530.0243.575.9710.7346.46
Upgrade
PB Ratio
0.610.821.442.353.9313.04
Upgrade
P/TBV Ratio
0.670.901.682.754.8515.84
Upgrade
P/FCF Ratio
---14.0221.63832.15
Upgrade
P/OCF Ratio
---10.4516.46477.40
Upgrade
EV/Sales Ratio
3.6210.1925.034.348.8146.45
Upgrade
EV/EBITDA Ratio
---8.6215.1067.32
Upgrade
EV/EBIT Ratio
---9.3616.1769.40
Upgrade
EV/FCF Ratio
---10.1917.76831.92
Upgrade
Debt / Equity Ratio
0.060.060.070.070.040.01
Upgrade
Debt / EBITDA Ratio
---0.320.180.03
Upgrade
Debt / FCF Ratio
---0.400.220.34
Upgrade
Asset Turnover
0.020.020.030.340.320.45
Upgrade
Inventory Turnover
---108.8169.8671.97
Upgrade
Quick Ratio
8.568.956.938.377.447.81
Upgrade
Current Ratio
10.159.817.338.677.717.86
Upgrade
Return on Equity (ROE)
-15.60%-14.75%-12.27%14.03%16.54%28.29%
Upgrade
Return on Assets (ROA)
-12.94%-12.41%-9.79%9.83%10.99%18.95%
Upgrade
Return on Capital (ROIC)
-15.86%-15.03%-11.65%11.81%13.44%22.89%
Upgrade
Return on Capital Employed (ROCE)
---15.80%17.10%17.30%
Upgrade
Earnings Yield
-26.83%-18.82%-8.84%5.47%3.81%1.10%
Upgrade
FCF Yield
-22.90%-21.60%-7.29%7.13%4.62%0.12%
Upgrade
Buyback Yield / Dilution
-1.78%-1.79%8.15%1.09%-20.96%-73.88%
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q